gms | German Medical Science

72. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

06.06. - 09.06.2021

The combination therapy of tumour treating fields with the TERT-inhibitor eribulin shows synergistic antiproliferative effects on human glioblastoma cells

Die Kombinationstherapie von Tumor Treating Fields mit dem TERT-Inhibitor Eribulin zeigt synergistische antiproliferative Effekte an humanen Glioblastomzellen

Meeting Abstract

  • presenting/speaker Piet Beusker - Justus-Liebig Universität Gießen, Klinik für Neurochirurgie, Gießen, Deutschland
  • Hanna Goett - Justus-Liebig Universität Gießen, Klinik für Neurochirurgie, Gießen, Deutschland
  • Malgorzata A. Kolodziej - Justus-Liebig Universität Gießen, Klinik für Neurochirurgie, Gießen, Deutschland
  • Eberhard Uhl - Justus-Liebig Universität Gießen, Klinik für Neurochirurgie, Gießen, Deutschland
  • Marco Stein - Justus-Liebig Universität Gießen, Klinik für Neurochirurgie, Gießen, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 72. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgie. sine loco [digital], 06.-09.06.2021. Düsseldorf: German Medical Science GMS Publishing House; 2021. DocP152

doi: 10.3205/21dgnc437, urn:nbn:de:0183-21dgnc4371

Veröffentlicht: 4. Juni 2021

© 2021 Beusker et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Objective: Treatment of glioblastoma (GBM) is challenging. Past milestones in the therapy were the addition of radiation therapy with temozolomide (TMZ), and the treatment with Tumor Treating Fields (TTFields) during TMZ maintenance. The aim of the study was to analyze, for the first time, the effects of the TERT-inhibitor eribulin in combination with TTFields on cell death and clonogenicity of human GBM.

Methods: Human GBM cells of the established cell lines U87, A172 and U251, as well as two patient-derived cell lines (447 and 455), were treated with eribulin, TTFields, or both modalities. After 72 hours of therapy, cell counts were measured. Additionally, clonogenic assays were performed. Cell death was analyzed using annexin V staining and fluorescence-activated cell scanning (FACS). The mean differences between cell counts, clonogenic fractions and FACS were evaluated.

Results: The mean surviving fractions over all cell lines (Figure 1 [Fig. 1]) were 42.6±SD % for eribulin, 35.7±% for TTFields, and 15.2±SD% for the combination. The mean annexin positive fractions over all cell lines were 12.8±SD% (control), 30.1±SD% (eribulin), 35.3±% (TTFields), and 75.5±SD% (combination), respectively. The mean clonogenic fractions over all cell lines (Figure 2 [Fig. 2]) were 19.1±SD% for eribulin and 33.6±SD% for TTFields. In the combination therapy, synergistic effects with a decreased mean of 3.2±SD% clonogenic fractions were observed.

Conclusion: Eribulin increases cell death and reduces clonogenicity in human GBM cells. Furthermore, for the combined treatment of TTFields and eribulin synergistic effects on cell proliferation were observed. Our data highlight the therapeutic potential of eribulin used in combination with TTFields and offer important insights for possible new effective GBM therapies.